Learn about options for managing the inflammatory bowel disease ulcerative colitis, including prescription medications, ...

An expert clinician expands on efficacy results seen in a study comparing intravenous and subcutaneous biologics.

Approval of the dual-acting interleukin (IL)-23 inhibitor in ulcerative colitis was based on findings from QUASAR, an ongoing ...

News item explaining ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo and Wenzela) and the switch from Stelara ...

2. Development of Janus Kinase (JAK) Inhibitors: Oral JAK inhibitors such as tofacitinib have been approved for the treatment of ulcerative colitis, offering an alternative to biologics for ...

Tremfya’s ulcerative colitis approval on Wednesday comes as Johnson & Johnson’s blockbuster immunotherapy Stelara continues to face growing competition from biosimilars.

Although these agents come with many benefits, they have also been known to increase the risk of infection due to their ...

The FDA has approved Tremfya® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

Increasing incidences and prevalence of ulcerative colitis, demand for drugs has been increased across the globe. The North America region emerged as the largest market for the ulcerative colitis drug ...

Truelove and Witts published the first placebo-controlled, randomised clinical trial in inflammatory bowel disease (IBD), which showed the superiority of cortisone for the treatment of acute ...

Johnson & Johnson already has a major presence in the crowded inflammatory bowel disease (IBD) space with its popular Stelara ...

Johnson & Johnson (JNJ) said that the U.S. Food and Drug Administration has approved TREMFYA (guselkumab) for the treatment of adults ...